Transient Interruption of Arterial Thrombosis by Inhibition of Factor Xa Results in Long-term Antithrombotic Effects in Baboons

Summary

Recombinant tick anticoagulant peptide (r-TAP) is a potent and specific inhibitor of activated coagulation factor X which effectively interrupts in vivo arterial thrombosis during treatment. It is, however, uncertain if it also affects thrombosis after treatment is stopped. This was tested in a baboon model of arterial thrombosis where platelet deposition onto Dacron vascular graft segments, inserted as extensions into permanent femoral arteriovenous shunts, was measured. The baboons were intravenously treated with 10 μg/kg/min (low dose, aPTT = 39 ± 1 s) and 25 μg/kg/min (high dose, aPTT = 58 ± 2 s) r-TAP for two hours. During treatment the r-TAP inhibited thrombin formation and dose-dependently interrupted platelet deposition onto the graft segment. This effect lasted for up to two hours after treatment with the low dose. Following treatment with the high dose, the graft segments were kept in place for 53 h. After treatment was stopped, platelets again deposited, but at a much lower rate than in control studies. Maximum deposition was approximately 38% lower than in the control studies. Total platelet deposition over 55 h, calculated as the area under the deposition curve, was approximately 40% (p <0.05) less than in the control studies. A significant shortening in the mean platelet life span and an approximately 15-fold increase in thrombin-antithrombin III complexes during the first 31 h indicated that the thrombus surface remained thrombogenic and that the effect of r-TAP was transient. We have shown that 2 h of treatment with a full antithrombotic dose of r-TAP markedly reduced both the rate of platelet deposition after treatment was stopped and the total number of platelets deposited over 55 h. This was in spite of the finding that the antithrombotic effect of r-TAP was transient.

• References

• 1 Wietz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 2 Eisenberg PR, Siegel JE, Abendschein DR, Miletich JP. Importance of factor Xa in determining the progoagulant activity of whole blood clots. J Clin Invest 1993; 91: 1877-1883
• 3 Cadroy Y, Harker LA. Platelets, thrombosis and antithrombotic therapies. In: Cardiovascular Pharmacology. Antonaccio M. ed 03. rd ed Raven Press, Publishers; New York, N.Y: 1990. pp 515-539
• 4 Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1066
• 5 Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide; a potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991; 84: 1741-1748
• 6 Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide is a novel inhibitor of blood coagulation factor Xa. Science 1990; 248: 593-596
• 7 Jordan SP, Waxman L, Smith DE, Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990; 29: 11095-11099
• 8 Lynch JJ, Sitko GR, Mellot MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddle T, Vlasuk GP. Maintenance of coronary artery patency following thrombolysis with front load plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994; 28: 78-85
• 9 Vlasuk GP, Ramjit D, Fujita T, Dunwiddle CT, Nutt EM, Smith DE, Shebuski RJ. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (TAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991; 65: 275-262
• 10 Kotzé HF, Lamprecht S, Badenhorst PN. A four hour infusion of r-hirudin results in long-term inhibition of arterial-type thrombosis in baboons. Blood 1995; 85: 3158-3163
• 11 Hanson SR, Kotzé HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts. A model of acute thrombosis in baboons. Arteriosclerosis 1985; 05: 595-603
• 12 Hanson SR, Harker LA. Baboon models of acute arterial thrombosis. Thromb Haemost 1987; 5 (08) 801-805
• 13 Hanson SR, Harker LA. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin, D-Phenylalanyl-L-prolyl-L-argenyl chloromethyl ketone (FPRCH₂CL). Proc Natl Acad Sci USA 1988; 85: 3184-3188
• 14 Savage B, Me FaddenPR, Hanson SR, Harker LA. The relation of platelet density to platelet age: Survival of low- and high density¹¹¹In-labelled platelets in baboons. Blood 1986; 68: 386-93
• 15 Kotzé HF, Lamprecht S, Badenhorst PN, Van WykV, Roodt JP, Alexander K. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by BAY U3405, a thromboxane A₂-receptor antagonist. Thromb Haemost 1993; 70: 672-675
• 16 Kotzé HF, HeynsA duP, Lötter MG, Pieters H, Roodt JP, Sweetlove MA, Badenhorst PN. Comparison of oxine and tropolone methods for labelling platelets with¹¹¹indium. J Nucl Med 1991; 32: 62-66
• 17 Kotzé HF, Lötter MG, Badenhorst PN, HeynsA duP. Kinetics of¹¹¹In- platelets in the baboon. I. Isolation and labelling of a viable and representative platelet populatio. Thromb Haemost 1985; 53: 404-407
• 18 Nagai H, Handa M, Kawai Y, Watanabe K, Ikeda Y. Evidence that plasma fibrinogen and platelet membrane GP IIB/IIIA are involved. Thromb Res 1993; 71: 467-477
• 19 Gemmel CH, Ramirez SM, Yeo EL, Sefton MV. Platelet activation in whole blood by artificial surfaces: Identification of platelet-derived microparticles and activated platelet binding to leucocytes as material induced activation events. J Lab Clin Med 1995; 125: 276-287
• 20 Packham M. Platelet function inhibitors. Thromb Haemost 1983; 50: 610-619
• 21 Hanson SR, Kotzé HF, Pieters H, HeynsA duP. Analysis of In-111-platelet kinetics and imaging in patients with aortic grafts and abdominal aneurysms. Arteriosclerosis 1990; 10: 1037-1044
• 22 Harker LA, Hanson SR, Runge MS. Thrombin hypothesis of thrombus generation and vascular legion formation. Am J Cardiol 1995; 75: 12B-17B
• 23 Lumsden AB, Kelly AB, Schneider PA, Krupski WC, Dodson T, Hanson SR, Harker LA. Lasting safe interruption of endarterectomy thrombosis by transiently infused antithrombin peptide D-Phe-Pro-ArgCH₂Cl in baboons. Blood 1993; 81: 1762-1770
• 24 Fuster V, Chesebro JH, Badimon L, Offord KP, Wahner HW. Platelet survival. In: Measurement of Platelet Function. Harker LA, Zimmerman TS. (eds) Churchill-Livingston; New York, N.Y: 1983. pp 189-215
• 25 Kotzé HF, HeynsA duP, Van WykV, Steyn JG, Duyvené De WitLJ, Badenhorst PN. The sensitivity of tests to detect in vivo platelet activation induced by the removal of arterial endothelium of the baboon (Papio ursinus). S Afr Med J 1990; 78: 271-276